(Q27852787)

English

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial (English)

1 reference

13 November 2016

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Caicun Zhou

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Cheng-Ping Hu

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jifeng Feng

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Shun Lu

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yunchao Huang

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Wei Li

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Mei Hou

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jian Hua Shi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Kye Young Lee

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Chong-Rui Xu

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dan Massey

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Miyoung Kim

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yang Shi

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sarayut L Geater

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

February 2014

0 references

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

213-222

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging ethnic differences in lung cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Diarrhea associated with afatinib: an oral ErbB family blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970604-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70604-1

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24439929%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852787&oldid=1603541986"